JAK/STAT Inhibition Normalizes Lipid Composition in 3D Human Epidermal Equivalents Challenged with Th2 Cytokines
Cells · 2024
DOI: 10.3390/cells13090760 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Enrica Flori und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cutaneous Physiopathology and Integrated Center of Metabolomics Research, San Gallicano Dermatological Institute, IRCCS, 00144 Rome, It…. Hauptthemen laut MEDLINE: Cytokines, Janus Kinases, Lipid Metabolism, STAT Transcription Factors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer (United States), Italian Ministry of Health (Ricerca Corrente 2024).
Abstract (Originalsprache)
Derangement of the epidermal barrier lipids and dysregulated immune responses are key pathogenic features of atopic dermatitis (AD). The Th2-type cytokines interleukin IL-4 and IL-13 play a prominent role in AD by activating the Janus Kinase/Signal Transduction and Activator of Transcription (JAK/STAT) intracellular signaling axis. This study aimed to investigate the role of JAK/STAT in the lipid perturbations induced by Th2 signaling in 3D epidermal equivalents. Tofacitinib, a low-molecular-mass JAK inhibitor, was used to screen for JAK/STAT-mediated deregulation of lipid metabolism. Th2 cytokines decreased the expression of elongases 1, 3, and 4 and serine-palmitoyl-transferase and increased that of sphingolipid delta(4)-desaturase and carbonic anhydrase 2. Th2 cytokines inhibited the synthesis of palmitoleic acid and caused depletion of triglycerides, in association with altered phosphatidylcholine profiles and fatty acid (FA) metabolism. Overall, the ceramide profiles were minimally affected. Except for most sphingolipids and very-long-chain FAs, the effects of Th2 on lipid pathways were reversed by co-treatment with tofacitinib. An increase in the mRNA levels of CPT1A and ACAT1, reduced by tofacitinib, suggests that Th2 cytokines promote FA beta-oxidation. In conclusion, pharmacological inhibition of JAK/STAT activation prevents the lipid disruption caused by the halted homeostasis of FA metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Cutaneous Physiopathology and Integrated Center of Metabolomics Research, San Gallicano Dermatological Institute, IRCCS, 00144 Rome, Italy.
- Genetic Research, Molecular Biology and Dermatopathology Unit, San Gallicano Dermatological Institute, IRCCS, 00144 Rome, Italy.
ORCID-Profile: Enrica Flori, Alessia Cavallo, Sarah Mosca, Anna Di Nardo, Grazia Bottillo, Miriam Maiellaro, Emanuela Camera, Giorgia Cardinali
Förderung
- Pfizer (United States)
- Italian Ministry of Health (Ricerca Corrente 2024)
Zitieren
APA
Flori, E., Cavallo, A., Mosca, S., Kovacs, D., Cota, C., Zaccarini, M., Di Nardo, A., Bottillo, G., Maiellaro, M., Camera, E., & Cardinali, G. (2024). JAK/STAT Inhibition Normalizes Lipid Composition in 3D Human Epidermal Equivalents Challenged with Th2 Cytokines. Cells. https://doi.org/10.3390/cells13090760
Vancouver
Flori E, Cavallo A, Mosca S, Kovacs D, Cota C, Zaccarini M, et al. JAK/STAT Inhibition Normalizes Lipid Composition in 3D Human Epidermal Equivalents Challenged with Th2 Cytokines. Cells. 2024. doi:10.3390/cells13090760
BibTeX
@article{Flori2024,
author = {Flori, Enrica and Cavallo, Alessia and Mosca, Sarah and Kovacs, Daniela and Cota, Carlo and Zaccarini, Marco and Di Nardo, Anna and Bottillo, Grazia and Maiellaro, Miriam and Camera, Emanuela and Cardinali, Giorgia},
title = {JAK/STAT Inhibition Normalizes Lipid Composition in 3D Human Epidermal Equivalents Challenged with Th2 Cytokines},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13090760}
}
EUVIMED